CD19 and neoplasm: To focus CD47 blockade on tumor cells, we generated two bispecific antibodies (biAbs) pairing a high affinity arm targeting a tumor associated antigen (TAA), i.e., CD19 or mesothelin (MSLN), to an optimized lower affinity arm targeting CD47 and investigated their efficacy in xenograft tumor models.